Linked Life Data

9371345

Source:http://linkedlifedata.com/resource/pubmed/id/9371345

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1998-1-23
pubmed:abstractText
We investigated the pharmacokinetics of zidovudine, zalcitabine, and saquinavir in AIDS Clinical Trial Group protocol 229. Patients received either saquinavir, zalcitabine, or a combination of both, together with zidovudine three times a day. Approximately 100 patients were enrolled in each treatment arm, and intensive pharmacokinetic studies were performed on about 25 patients per arm at weeks 1 and 12. We estimated the pharmacokinetic parameters of all three drugs by using parametric and nonparametric methods. The mean values of the pharmacokinetic parameters of zidovudine (clearance [CL]/bioavailability [F], 168 liters/h; volume of distribution [V]/F, 185 liters; half-life, 0.76 h) and zalcitabine (CL/F, 25 liters/h; V/F, 92.2 liters; half-life, 2.7 h) were similar to those reported previously. For saquinavir, the mean pharmacokinetic parameter estimates using parametric methods were as follows: maximum concentration of drug in serum [Cmax], 70.8 ng/ml; time to Cmax, 3.11 h; area under the curve, 809 ng x h/ml; CL/F, 989 liters/h; V/F, 1,503 liters; half-life, 1.38 h. For all three drugs, clearance decreased with age. Weight did not influence the clearance of zidovudine, but the clearance of zalcitabine and saquinavir increased with weight. There were no differences in pharmacokinetic parameters between study weeks and arms, suggesting that there is no change in kinetics with chronic administration and that there are no significant pharmacokinetic interactions among these three drugs.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-1345755, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-1722897, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-2350441, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-2852679, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-3165603, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-3549120, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-7693435, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-8098029, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-8257138, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-8598838, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-8633817, http://linkedlifedata.com/resource/pubmed/commentcorrection/9371345-9371346
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
41
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2428-32
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
pubmed:affiliation
Division of Clinical Pharmacology, Stanford University, California, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S., Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II